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Preclinical evaluation of the PARP inhibitor rucaparib in 
combination with PD-1 and PD-L1 inhibition in a syngeneic 
BRCA1 mutant ovarian cancer model 
 
Background: Rucaparib (CO-338) is an oral small molecule inhibitor 
of poly(ADP-ribose) polymerase (PARP)-1, PARP-2 and PARP-3 that 
has shown clinical activity in patients with BRCA1 and BRCA2 
mutated advanced ovarian cancer. Monoclonal antibodies against 
programmed death receptor-1 (PD-1) and programmed death-ligand 
(PD-L1) have also shown efficacy in advanced ovarian cancer 
patients. It has been reported that BRCA1 and BRCA2 mutated tumors 
have a higher mutational load and increased CD8+ T cell infiltration, 
suggesting that the combination of rucaparib and immune 
checkpoint inhibition may be complementary. However, PARP 
inhibition has also been reported to have an immunosuppressive 
effect in preclinical studies. 
Methods: Subcutaneous syngeneic models using the BRCA1 wild-
type C2Km (P53-/-, myc, Kras-G12D, Akt-myr) and BRCA1 mutant 
BrKras (BRCA1-/-; P53-/-; myc; Kras-G12D; Akt-myr) murine ovarian 
cell lines were developed in the murine FVB/N background. 
Antibodies targeting PD-1 (RMP1-14) and PD-L1 (10F.9G2) were 
dosed by intraperitoneal injection at 5-10 mg/kg twice weekly, while 
rucaparib was administered by oral gavage at 150 mg/kg twice daily. 
Treatment was initiated at a tumor volume of ~150mm3 
(n=15/group). Animals were dosed for 21 days, and tumors were 
allowed to regrow to day 76. 
Results: In vitro cytotoxicity assays demonstrated that rucaparib 
was 155-fold more potent in the BRCA1 deficient BrKras cell line 
(IC50 = 84 nM) than the isogenic BRCA1 wild-type C2Km cell line 
(IC50 = 13 μM). An in vivo study using the syngeneic BrKras model 
was performed in mice treated with: vehicle, rucaparib, PD-1, PD-L1, 
rucaparib+PD-1, and rucaparib+PD-L1. All monotherapy and 
combination groups resulted in significant tumor growth inhibition 
and were followed for survival analysis. The median survival time 
(MST) and % cures (defined as undetectable growth at Day 76 post-
tumor implantation) for vehicle, PD-L1, PD-1 and rucaparib 
monotherapy treated animals was 34 days (0%), 41 days (13%), 76 
days (40%) and >76 days (56%), respectively. The rucaparib+PD-1 
and rucaparib+PD-L1 combination groups demonstrated greater 
efficacy than the monotherapies, with a MST of >76 days (100%) and 
>76 days (88%), respectively. Dose response and immune profiling 
studies are ongoing. In vivo studies were also performed in the 
BRCA1/2 wild-type models EMT-6, Pan02, and MC38. As expected, as 
a single agent, rucaparib showed limited activity in these 
homologous recombination competent models, whereas a range of 
tumor growth inhibition was observed with monotherapy PD-L1 
treatment. No impact on anti-tumor activity was observed in animals 
treated with rucaparib+PD-L1 as compared to PD-L1 monotherapy in 
the BRCA1/2 wild-type syngeneic models examined. 
Conclusions: The combination of rucaparib with PD-1 and PD-L1 
inhibition improved survival in a BRCA1 mutant syngeneic model. 
